more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Research for AMGN

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: Aimovig: Total [$M...		323	414	317	378	306
Product Sales: EVENITY: Total [$M...		1,160	787	530	350	189
Product Sales: Otezla: Total [$M]		2,188	2,288	2,249	2,195	178
Product Sales: AMJEVITA/AMGEVITA:...		626	460	439	331	215
Product Sales: MVASI: Total [$M]		800	901	1,166	798	127
Product Sales: TEZSPIRE: Total [$...		567	170	0	--	--
Product Sales: TAVNEOS: Total [$M...		134	21	0	--	--
Product Sales: TEPEZZA: Total [$M...	--	448	0	--	--	--
Product Sales: KRYSTEXXA: Total [...	--	272	0	--	--	--
Product Sales: UPLIZNA: Total [$M...	--	65	0	--	--	--
Product Sales: Ultra Rare product...	--	164	0	--	--	--
Revenue: Product sales [$M]		26,910	24,801	24,297	24,240	22,204
Product Sales: Neulasta: Total [$...		848	1,126	1,734	2,293	3,221
Revenue: Other revenues [$M]		5,263	5,220	5,321	5,724	5,538
Product Sales: Other products: To...		709	639	339	283	312
Product Sales: EPOGEN: Total [$M]		226	506	521	598	867
Product Sales: Aranesp: Total [$M...		1,362	1,421	1,480	1,568	1,729
Product Sales: Prolia: Total [$M]		4,048	3,628	3,248	2,763	2,672
Product Sales: Repatha: Total [$M...		1,635	1,296	1,117	887	661
Product Sales: Parsabiv: Total [$...		362	382	280	716	630
Product Sales: KYPROLIS: Total [$...		1,403	1,247	1,108	1,065	1,044
Product Sales: XGEVA: Total [$M]		2,112	2,014	2,018	1,899	1,935
Product Sales: Vectibix: Total [$...		984	893	873	811	744
Product Sales: Nplate: Total [$M]		1,477	1,307	1,027	850	795
Product Sales: BLINCYTO: Total [$...		861	583	472	379	312
Product Sales: Enbrel: Total [$M]		3,697	4,117	4,465	4,996	5,226
Product Sales: LUMAKRAS/LUMYKRAS:...		280	285	90	0	--
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: BLINCYTO: US [$M]		566	336	278	231	176
Product Sales: BLINCYTO: ROW [$M]		295	247	194	148	136
Product Sales: Aimovig: US [$M]		303	398	313	378	306
Product Sales: Aimovig: ROW [$M]		20	16	4	0	0
Product Sales: EVENITY: US [$M]		809	533	331	191	42
Product Sales: EVENITY: ROW [$M]		351	254	199	159	147
Product Sales: Otezla: US [$M]		1,777	1,886	1,804	1,790	139
Product Sales: Otezla: ROW [$M]		411	402	445	405	39
Product Sales: MVASI: US [$M]		511	602	826	656	121
Product Sales: MVASI: ROW [$M]		289	299	340	142	6
Product Sales: AMJEVITA/AMGEVITA:...		126	0	0	0	0
Product Sales: AMJEVITA/AMGEVITA:...		500	460	439	331	215
Product Sales: LUMAKRAS/LUMYKRAS:...		197	222	82	--	--
Product Sales: LUMAKRAS/LUMYKRAS:...		83	63	8	--	--
Product Sales: TAVNEOS: US [$M]		126	16	0	--	--
Product Sales: TAVNEOS: ROW [$M]		8	5	0	--	--
Product Sales: TEPEZZA: US [$M]	--	441	0	--	--	--
Product Sales: TEPEZZA: ROW [$M]	--	7	0	--	--	--
Product Sales: KRYSTEXXA: US [$M]	--	272	0	--	--	--
Product Sales: UPLIZNA: US [$M]	--	60	0	--	--	--
Product Sales: UPLIZNA: ROW [$M]	--	5	0	--	--	--
Product Sales: Ultra Rare product...	--	162	0	--	--	--
Product Sales: Ultra Rare product...	--	2	0	--	--	--
Product Sales: Aranesp: US [$M]		452	521	537	629	758
Product Sales: Aranesp: ROW [$M]		910	900	943	939	971
Product Sales: Enbrel: US [$M]		3,650	4,044	4,352	4,855	5,050
Product Sales: Enbrel: ROW [$M]		47	73	113	141	176
Product Sales: Neulasta: US [$M]		710	959	1,514	2,001	2,814
Product Sales: Neulasta: ROW [$M]		138	167	220	292	407
Product Sales: Vectibix: US [$M]		461	396	347	342	316
Product Sales: Vectibix: ROW [$M]		523	497	526	469	428
Revenue: Product: Other: US [$M]		549	296	202	109	105
Revenue: Product: Other: Internat...		160	135	137	174	207
Product Sales: EPOGEN: US [$M]		226	506	521	598	867
Product Sales: Nplate: US [$M]		996	848	566	485	480
Product Sales: Nplate: ROW [$M]		481	459	461	365	315
Revenue: Product: International [...		7,638	7,058	7,011	6,255	5,673
Revenue: Product: US [$M]		19,272	17,743	17,286	17,985	16,531
Product Sales: Prolia: US [$M]		2,733	2,465	2,150	1,830	1,772
Product Sales: Prolia: ROW [$M]		1,315	1,163	1,098	933	900
Product Sales: Repatha: US [$M]		793	608	557	459	376
Product Sales: Repatha: ROW [$M]		842	688	560	428	285
Product Sales: Parsabiv: US [$M]		228	253	150	605	550
Product Sales: Parsabiv: ROW [$M]		134	129	130	111	80
Product Sales: KYPROLIS: US [$M]		921	850	736	710	654
Product Sales: KYPROLIS: ROW [$M]		482	397	372	355	390
Product Sales: XGEVA: US [$M]		1,527	1,480	1,434	1,405	1,457
Product Sales: XGEVA: ROW [$M]		585	534	584	494	478

Revenue - Line of Business Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Product Sales: Aimovig: Total [$M...		82	85	65	78	94
Product Sales: EVENITY: Total [$M...		399	391	342	318	307
Product Sales: Otezla: Total [$M]		564	544	394	629	567
Product Sales: AMJEVITA/AMGEVITA:...		166	133	168	160	152
Product Sales: MVASI: Total [$M]		195	157	202	188	213
Product Sales: TEZSPIRE: Total [$...		269	234	173	177	161
Product Sales: TAVNEOS: Total [$M...		80	71	51	44	37
Product Sales: TEPEZZA: Total [$M...		488	479	424	448	0
Product Sales: KRYSTEXXA: Total [...		310	294	235	272	0
Product Sales: UPLIZNA: Total [$M...		106	92	80	65	0
Product Sales: Ultra Rare product...		188	187	169	164	0
Revenue: Product sales [$M]		8,503	8,041	7,118	7,833	6,903
Product Sales: Neulasta: Total [$...		110	105	118	239	124
Revenue: Other revenues [$M]		352	347	329	363	355
Product Sales: Other products: To...		281	346	357	175	281
Product Sales: EPOGEN: Total [$M]		33	32	41	55	50
Product Sales: Aranesp: Total [$M...		337	348	349	319	323
Product Sales: Prolia: Total [$M]		1,045	1,165	999	1,107	986
Product Sales: Repatha: Total [$M...		567	532	517	417	406
Product Sales: Parsabiv: Total [$...		70	106	105	89	95
Product Sales: KYPROLIS: Total [$...		378	377	376	350	349
Product Sales: XGEVA: Total [$M]		541	562	561	527	519
Product Sales: Vectibix: Total [$...		282	270	247	251	252
Product Sales: Nplate: Total [$M]		456	346	317	386	419
Product Sales: BLINCYTO: Total [$...		327	264	244	241	220
Product Sales: Enbrel: Total [$M]		825	909	567	1,015	1,035
Product Sales: LUMAKRAS/LUMYKRAS:...		98	85	82	77	52
Revenue - Geographic Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Product Sales: BLINCYTO: US [$M]		237	165	153	148	147
Product Sales: BLINCYTO: ROW [$M]		90	99	91	93	73
Product Sales: Aimovig: US [$M]		77	80	65	73	88
Product Sales: Aimovig: ROW [$M]		5	5	5	5	6
Product Sales: EVENITY: US [$M]		289	281	236	239	214
Product Sales: EVENITY: ROW [$M]		110	110	106	79	93
Product Sales: Otezla: US [$M]	--	460	432	293	526	462
Product Sales: Otezla: ROW [$M]		104	112	101	103	105
Product Sales: MVASI: US [$M]		136	100	105	127	140
Product Sales: MVASI: ROW [$M]		59	57	97	61	73
Product Sales: AMJEVITA/AMGEVITA:...		28	-9	30	33	23
Product Sales: AMJEVITA/AMGEVITA:...		138	142	138	127	129
Product Sales: LUMAKRAS/LUMYKRAS:...		53	55	53	51	48
Product Sales: LUMAKRAS/LUMYKRAS:...		45	30	29	26	4
Product Sales: TAVNEOS: US [$M]		74	61	45	42	32
Product Sales: TAVNEOS: ROW [$M]		6	10	6	2	5
Product Sales: TEPEZZA: US [$M]		482	478	419	441	0
Product Sales: TEPEZZA: ROW [$M]	--	6	1	5	7	0
Product Sales: KRYSTEXXA: US [$M]		310	294	235	272	0
Product Sales: UPLIZNA: US [$M]		74	77	70	60	0
Product Sales: UPLIZNA: ROW [$M]		32	15	10	5	0
Product Sales: Ultra Rare product...		180	175	166	162	0
Product Sales: Ultra Rare product...		8	12	3	2	0
Product Sales: Aranesp: US [$M]		105	91	100	107	107
Product Sales: Aranesp: ROW [$M]		232	257	249	212	216
Product Sales: Enbrel: US [$M]		817	902	561	1,005	1,026
Product Sales: Enbrel: ROW [$M]		8	7	6	10	9
Product Sales: Neulasta: US [$M]		84	75	87	208	92
Product Sales: Neulasta: ROW [$M]		26	30	31	31	32
Product Sales: Vectibix: US [$M]		132	133	120	116	116
Product Sales: Vectibix: ROW [$M]		150	137	127	135	136
Revenue: Product: Other: US [$M]		228	292	301	137	136
Revenue: Product: Other: Internat...		53	54	56	38	31
Product Sales: EPOGEN: US [$M]		33	32	41	55	50
Product Sales: Nplate: US [$M]		345	214	190	252	322
Product Sales: Nplate: ROW [$M]		111	132	127	134	97
Revenue: Product: International [...		2,172	2,201	2,145	1,963	1,857
Revenue: Product: US [$M]		5,979	5,840	4,973	5,870	4,691
Product Sales: Prolia: US [$M]		683	770	657	746	673
Product Sales: Prolia: ROW [$M]		362	395	342	361	313
Product Sales: Repatha: US [$M]		281	270	273	201	183
Product Sales: Repatha: ROW [$M]		286	262	244	216	223
Product Sales: Parsabiv: US [$M]		32	67	65	57	59
Product Sales: Parsabiv: ROW [$M]		38	39	40	32	36
Product Sales: KYPROLIS: US [$M]		238	240	234	222	231
Product Sales: KYPROLIS: ROW [$M]		140	137	142	128	118
Product Sales: XGEVA: US [$M]		373	399	366	382	374
Product Sales: XGEVA: ROW [$M]		168	163	195	145	145

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators